

Warsaw, 16.03.2026

PRICE INQUIRY No. SEMA/76/PR142486 /2026
conducted in the market research mode

In connection with the implementation of the project entitled "*Development and development of an innovative solution - a generic drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes*" financed from the state budget from the Medical Research Agency, Zakłady Farmaceutyczne Polpharma S.A., ask for the submission of bids for **the supply of the active substance – semaglutide and standards**

I. NAME AND ADDRESS OF THE CONTRACTING AUTHORITY

Zakłady Farmaceutyczne Polpharma S.A.
19 Pelpińska Street, 83-200 Starogard Gdański

II. PROCEDURE OF AWARDING THE CONTRACT

- II.1.** This inquiry is not subject to the provisions of the Act of 11 September 2019. Public Procurement Law (i.e. Journal of Laws of 2019, item 2019)
- II.2.** Proceedings conducted in the market research mode, in a purposeful and economical manner, observing the following principles:
- 1) obtaining the best results from given expenditures;
 - 2) optimal selection of methods and means to achieve the assumed objectives
 - 3) openness, fair competition and equal treatment of contractors

III. DESCRIPTION OF THE SUBJECT OF THE PRICE INQUIRY

III.1. The subject of the price inquiry is the purchase and supply of **certified active pharmaceutical substances:**

- **Semaglutide, (C187H291N45O59, CAS 910463-68-2) obtained by Solid Phase Peptide Synthesis**
- **Analytical Standards**
- **Impurities Standards**

III.2. CPV code: 24950000-8 Specialty chemical products

III.3. Scope of the request for proposal:

III.3.1. Providing a total of 1500 grams of Semaglutide including:

- a) 700 grams from an independent production batch, divided into separate bags:-1) One bag of 370 grams
- 2) One bag of 300 grams
- 3) Two bags of 6 grams each
- 4) Eighteen bags of 1 gram

(b) 400 grams from a second independent production batch, divided into separate bags:



- 1) One bag of 370 grams
- 2) Two bags of 6 grams each
- 3) Eighteen bags of 1 gram each

(c) 400 grams from the third independent production batch, divided into separate bags:

- 1) One bag of 370 grams
- 2) Two bags of 6 grams each
- 3) Eighteen bags of 1 gram each

III.3.2. Semaglutide must meet the following requirements:

1. Production under the GMP regime
2. Water content not more than 7% (weight/weight)
3. Sodium cation content not more than 3% (w/w)
4. Total content of all related substances not more than 0,5%
5. No impurity with substituted residue 25Trp(4-hydroxybenzyl)
6. Content of labelled oligomers not more than 0,2%
7. Production batch not older than 9 months at the time of delivery

III.3.3. Supply of three sets of analytical standards for all peptide impurities and semaglutide standard:

- in the quantity necessary to carry out a full test for the release of 1 batch according to the manufacturer's specifications
- with certificates confirming the quality of the substances supplied (for impurities standards, e.g. data on purity >80%, water quantity, and in the case of semaglutide standard, information in accordance with point III.3.4.1.)
- with an expiry date of not less than 12 months.

III.3.4. Delivery of the primary API standard – Semaglutide in the amount of 1x100 mg, 6x50 mg

III. 3.4.1. The primary standard of Semaglutide should meet the following requirements:

- provide the CoA: semaglutide content (calculated on the basis of anhydrous, free of free acid radicals, ammonium ions and sodium ions) $\geq 99\%$ and the stated semaglutide content (as is basis); identity confirmed by two techniques, including at least LC-MS, the amount of sodium ions and anions, the amount of water, the residue of solvents, the specified impurities and their quantity (related substances). Additional information beyond CoA: information on the characterisation of the substance: AAA (amino acid composition analysis);
- Expiry date not shorter than 12 months.

III.3.5. Delivery of the following contaminant standards in the following quantities:

D-[ASP]9-Semaglutide	25mg
D-[Phe]6-Semaglutide	25mg
Fragment-[3- 31]- Semaglutide	25mg
[Glu] 17 - Semaglutide	15 mg
D-[Ser]8-Semaglutide	25mg
D-[His] 1 - Semaglutide	25mg

III.3.5.1. Impurities standards shall meet the following requirements:

- attached CoA, where the purity is given >80%, the amount of water;
- Expiry date not shorter than 12 months

IV. PLACE AND DATE OF EXECUTION OF THE PRICE INQUIRY

- IV.1. Deadline for the subject of the price inquiry: the required delivery date – maximum 60 calendar days from the date of placing the Order
- IV.2. Planned date of signing the agreement: March 2026
- IV.3. The subject of the inquiry must be delivered at the Seller's expense to the Buyer's registered office at the address: Zakłady Farmaceutyczne Polpharma Spółka Akcyjna, Warehouse in Starogard
- IV.4. The order will be generated immediately after the selection of the Contractor.
- IV.5. Bids with a deadline later than indicated in point IV.1 will be rejected

V. GENERAL REQUIREMENTS

- V.1. Along with the offer and delivery, the bidder will provide certificates for the ordered products.
- V.2. Required documents/certificates - for the active substance and standards.
- V.3. The minimum shelf life of the substance for point III.3.1 is to be **24 months** from the date of delivery of the order.
- V.4. The Contracting Authority does not allow equivalent products
- V.5. The Contracting Authority does not allow variant offers.
- V.6. The Contracting Authority does not allow quantities other than those specified.
- V.7. The Ordering Party does not allow other sizes of packaging.
- V.8. The Contracting Authority does not allow partial bids.
- V.9. Entities in relation to which the following circumstances occur are excluded from participation in the proceedings:
- a) described in Article 7(1) of the Act of 13 April 2022 on special arrangements for counteracting support for aggression against Ukraine and for the protection of national security;
 - b) as described in Article 5k of Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

Method of verifying the grounds/absence of grounds for exclusion:

The verification will take place on the basis of the Bidder's statement.

VI. DESCRIPTION OF THE CRITERIA THAT THE CONTRACTING AUTHORITY WILL FOLLOW WHEN SELECTING THE TENDER

- VI.1. When evaluating the bids, the Contracting Authority will be guided by the following criteria:
- total net price of the order – 100%,

- VI.3 The bid will be evaluated in accordance with the formula:

$$OP = Pc$$

where:

OP - point evaluation of the offer

PC - number of points obtained in the "Price" criterion

The number of points (PC) in the criterion "Total net price" will be calculated according to the formula:

$$P_C = \frac{C_N}{C_B} * 100 \text{ pkt}$$

where:

- PC - Number of points for the "Price" criterion
- CN - Of the unrejected bids, the lowest total net bid price
- CB - total net price of the examined offer

Bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland on the date of closing the deadline for submission of bids.

VI.4. The most advantageous bid will be considered to be the bid from among the unrejected bids, which in total

will get the highest number of points. A maximum of 100 points can be obtained by the Seller. The calculation will be performed to two decimal places.

VII. PLACE AND DATE OF SUBMISSION OF BIDS

VII.1. Bids must be submitted by **23.03.2026**.

- in electronic form (in the form of a scan of a signed document or a document signed with a qualified signature) to the following address: proces.ofertowy@polpharma.com

VII.2. The submission of an offer will be considered effective if the complete offer is received by the e-mail box with the address specified above within the time limit specified in this section.

VII.3. Bids submitted after the deadline will not be considered.

VIII. DESCRIPTION OF THE METHOD OF PREPARING THE OFFER, THE METHOD OF COMMUNICATION BETWEEN THE CONTRACTING AUTHORITY AND THE BIDDERS, PERSONS AUTHORIZED TO CONTACT

VIII.1. The bidder should prepare one price offer in accordance with the template form constituting Appendix No. 1 to the inquiry.

VIII.2. Submitting more than one bid for a given lot will result in the rejection of all bids submitted by the Bidder.

VIII.3. In the procedure, the Contracting Authority and the Tenderer shall submit statements, applications, notices and information in Polish or English

VIII.4. All notices, statements, requests and information provided in electronic form require immediate confirmation of receipt by each party upon request.

VIII.5. In the absence of confirmation of receipt of correspondence by the Bidder, the Ordering Party assumes that the correspondence sent by the Ordering Party to the e-mail address provided by the Bidder has been delivered to it in a way that allows it to become acquainted with its content.

VIII.6. In correspondence related to this inquiry, the Bidder should use the number **SEMA/76/PR142486/2026**.

VIII.7. The person authorized to communicate with the Bidders is Mr. Paweł Brzeziński.

VIII.8. The offer must be signed by persons authorized to represent the Bidder or acting on the basis of a power of attorney. The power of attorney should be attached to the offer.

VIII.9. Bidders are obliged to carefully read the information contained in the Price Enquiry.

VIII.10. The bidder submitting the bid remains bound by it for a period of 60 calendar days counting from the date of expiry of the deadline for submission of bids.

VIII.11. The tenderer may amend or withdraw its tender before the deadline for submission of tenders.

VIII.12. Bidders are obliged to carefully read the information contained in the Price Enquiry. In matters related to this inquiry, please contact the Ordering Party, e-mail: proces.ofertowy@polpharma.com

IX. CHANGE IN THE CONTENT OF THE AGREEMENT

IX.1. The Contracting Authority reserves the **right to make significant changes to the provisions of the Agreement** for the services offered in relation to the content of the offer on the basis of which the Contractor was selected, to the following extent and situations:

IX.1.1. changes in the provisions of law, to the extent affecting the performance of the Agreement (in particular changes in VAT rates);

IX.1.2. improvement of the technical parameters of the subject of the Agreement, resulting from the update of solutions due to technological progress, without affecting the gross lump sum price

IX.1.3. extension of the deadline for the performance of the Agreement as a result of the need to perform additional works, the performance of which is necessary for the proper performance of the Agreement, and the performance of which the Ordering Party, acting with due diligence, could not have foreseen in advance, subject to point IX.1.6 below;

IX.1.4. extension of the deadline for the performance of the Agreement as a result of force majeure along with all the consequences arising in connection with the extension of this deadline;

IX.1.5. changes in the parameters of the subject of the Agreement, not leading to a change in the nature of the Agreement - technological changes, in particular: the need to perform the Agreement with the use of technical/technological and material solutions other than those indicated in the Request for Proposal, in a situation where the application of the envisaged solutions would threaten non-performance or defective performance of the Agreement, subject to point IX.1.7. below;

IX.1.6. the changes concern the performance of additional supplies or services of the Contractor, not covered by the Agreement, if they have become necessary and the following conditions have been met together:- the change of the Contractor may not be made for economic or technical reasons, in particular related to the interchangeability or interoperability of equipment, services or installations ordered under the basic subject of the Agreement, - the change of the Contractor would cause a significant inconvenience or a significant increase in costs for the Ordering Party,
- the value of each subsequent change does not exceed 50% of the net value of the original subject of the Agreement;

IX.1.7. the change does not lead to a change in the nature of the Agreement and the following conditions have been met in total:

- the necessity to amend the Agreement is caused by circumstances that the Ordering Party, acting with due diligence, could not have foreseen,

- the value of the change does not exceed 50% of the net value of the original subject of the Agreement;

IX.1.8. The contractor is to be replaced by a new contractor:

- as a result of a merger, division, transformation, bankruptcy, restructuring or acquisition of the Contractor or its enterprise, provided that the new Contractor meets the conditions for participation in the procedure, there are no grounds for exclusion against it and it does not entail other material changes to the Agreement,

- as a result of the Contracting Authority's assumption of the Contractor's obligations towards its subcontractors.

IX.2. The contracting authority also provides for **the possibility of making insignificant changes to the provisions of the concluded Agreement** in relation to the content of the bid on the basis of which the Contractor was selected.

IX.3. Amendments to the Agreement will be introduced in the form of annexes signed by both Parties, and the possibility of their introduction depends on the acceptance by the Ordering Party.

X. OTHER INFORMATION

X.1. The bidder bears all costs related to the preparation and submission of the bid.

X.2. Until the expiry of the deadline for submission of bids, the Ordering Party reserves the right to change or supplement the content of this price inquiry.

IV.3. No verbal or telephone information, explanations or answers to inquiries addressed to the Ordering Party are provided.

IV.4. Any questions regarding this inquiry should be submitted by e-mail to the address indicated above no later than 3 days before the deadline for submitting bids.

IV.5. Answers to questions asked by potential Bidders and any clarifications of the content of the Inquiry will be published in the same form in which the original Inquiry was made available, with the principle of equal treatment of all potential Bidders

IV.6. The Contracting Authority reserves the right to check the credibility of the documents, statements, lists, data and information presented by the Bidders in the course of the evaluation of the bid.

IV.7. The Contracting Authority reserves the right to negotiate offers with the Bidder whose bid will receive the highest number of points, in particular in the event that the price offered by the Bidder exceeds the budget allocated by the Contracting Authority for the execution of the contract.

IV.8. If two or more Bidders obtain the same number of points, the most advantageous offer in terms of environmental and climate impact will be selected. For this purpose, the Contracting Authority has the right to call on the Bidders whose bids received the highest final number of points to supplement the bid by providing the information indicated by the Contracting Authority regarding the environmental impact of the subject of the bid.

IV.9. The Ordering Party reserves the right to cancel the procurement procedure without giving a reason.

IV.10. In the event of annulment of the procedure, the Bidder is not entitled to a claim for reimbursement of the costs of participation in the procedure.

V. LIST OF ATTACHMENTS

The following documents are attached to this Price Inquiry:

Designation of the attachment	Attachment Name
Appendix No. 1	Sample price form

Attachment No. 1 to the Price Inquiry No. SEMA/76/PR142486/2026

PRICE FORM

Bidder:

Full name (company) or name	
Registered office/place of residence/address of the main place of business	
E-mail address to which the Ordering Party should send correspondence related to the price inquiry	
NIP	
REGON	
Phone	
Person to contact the Ordering Party	

We offer the execution of the subject of the order Delivery of the active substance – semaglutide and standards , in accordance with the requirements of the Price Inquiry, for the **price:**

Subject of price inquiry Full description	J.M.	Quantity	Net price PLN/ EUR/ USD* per UU	Total Net Worth PLN / EUR /USD*	Total gross value PLN / EUR / USD*	Delivery time [calendar days from the date of placing the order]
Semaglutide	gram	1500				
Analytical Standards of All Peptide Impurities and Semaglutide Standard	set	3				
Primary API Standard – Semaglutide	milligram	100 + 6x50				

Impurities Standards	milligram	25				
		25				
		25				
		15				
		25				
		25				

differentiated in the request for quotation. *select the appropriate currency

Payment term for invoice days from the delivery of the goods. (minimum 30 days)

The bidder has the status of an SME / Large Entrepreneur*

* (delete unnecessary)

At the same time, we declare that:

- a. we have read the Price Inquiry with attachments and do not raise any objections and have obtained the necessary information to prepare the offer,
- b. the price includes a lump sum remuneration for all the Seller's obligations necessary to complete the subject of the Price Inquiry,
- c. we consider ourselves bound by this offer for a period of 60 calendar days from the expiry of the deadline for submission of offers,
- d. There are no circumstances in relation to us:
 1. described in Article 7(1) of the Act of 13 April 2022 on special arrangements for counteracting support for aggression against Ukraine and for the protection of national security;
 2. as described in Article 5k of Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

.....
(city and date)

.....
(signature of the person(s) authorized to submit
the declaration of intent on behalf of the Bidder)